Adam Nowlan
Experienced in Fibrosarcoma

Dr. Adam Nowlan

Radiation Oncology
Piedmont Healthcare
Piedmont Physicians Radiation Oncology Mountainside
200 Bill Hasty Blvd, 
Jasper, GA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth

Experienced in Fibrosarcoma
Piedmont Healthcare
Piedmont Physicians Radiation Oncology Mountainside
200 Bill Hasty Blvd, 
Jasper, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Adam Nowlan, MD is a board-certified radiation oncologist, currently practicing and serving as Medical Director of the radiation oncology department at Piedmont Hospital in Atlanta, GA.

Dr. Nowlan is very active in clinical research activities. He previously chaired the Piedmont Healthcare Institutional Review Board and is an active member of the Piedmont Hospital Oncology Scientific Review Committee.

Dr. Nowlan has been named to sit on the recently convened Piedmont Healthcare Oncology Clinical Governance Committee, responsible for executive guidance of system initiatives.

Dr. Nowlan serves as the Piedmont Healthcare principal investigator for the Radiation Therapy Oncology Group clinical trials that are open at Piedmont Hospital locations in Buckhead, Atlanta and Fayette.

Dr. Nowlan is a member of the clinical trials team at the recently launched Piedmont Hospital Brain Tumor Center.

Throughout his medical experience, Dr. Nowlan's work has appeared in several publications, and he has engaged in research projects and presentations on a wide variety of relevant radiation oncology subjects.

In his spare time, Dr. Nowlan enjoys skiing, watching roller derby and spending time with his wife and family.

Dr. Nowlan is rated as an Experienced provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Posterior Fossa Tumor, Astrocytoma, Lung Cancer, Pleuropulmonary Blastoma, and Awake Craniotomy.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 25 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Emory University School Of Public Health, 1997
Residency
Emory University School of Medicine, Radiation Oncology, 2006
Specialties
Radiation Oncology
Licenses
Radiology in GA
Board Certifications
American Board Of Radiology
Hospital Affiliations
Piedmont Mountainside Hospital Inc
Piedmont Cartersville Medical Center
Piedmont Hospital, Inc
Wellstar Kennestone Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Piedmont Physicians Radiation Oncology Mountainside
200 Bill Hasty Blvd, Jasper, GA 30143
Call: 706-299-2070

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


25 Clinical Trials

A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
Enrollment Status: Recruiting
Publish Date: November 13, 2025
Intervention Type: Radiation, Procedure, Drug
Study Drug: Memantine
Study Phase: Phase 3
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Enrollment Status: Recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Radiation
Study Drugs: Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Relugolix, Triptorelin
Study Phase: Phase 3
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Completed
Publish Date: December 09, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: October 31, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Radiation
Study Phase: Phase 3
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer
Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer
Enrollment Status: Suspended
Publish Date: September 05, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 2/Phase 3
Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): A Randomized Trial of Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer
Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): A Randomized Trial of Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 2
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients
A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients
Enrollment Status: Completed
Publish Date: February 17, 2025
Intervention Type: Drug, Radiation
Study Drugs: Anastrozole, Exemestane, Fulvestrant, Letrozole, Palbociclib, Tamoxifen
Study Phase: Phase 2
ARM: Axillary Reverse Mapping - a Prospective Trial to Study Rates of Lymphedema and Regional Recurrence After Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection with and Without Axillary Reverse Mapping
ARM: Axillary Reverse Mapping - a Prospective Trial to Study Rates of Lymphedema and Regional Recurrence After Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection with and Without Axillary Reverse Mapping
Enrollment Status: Active_not_recruiting
Publish Date: January 17, 2025
Intervention Type: Other, Drug, Procedure
Study Drug: Isosulfan Blue
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Depatuxizumab
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
Enrollment Status: Terminated
Publish Date: July 27, 2022
Intervention Type: Drug, Other
Study Drug: Varenicline
Study Phase: Phase 3
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: August 28, 2019
Intervention Type: Radiation
Study Phase: Phase 3
View 23 Less Clinical Trials

3 Total Publications

Chordoid glioma of the third ventricle: report of a rapidly progressive case.
Chordoid glioma of the third ventricle: report of a rapidly progressive case.
Journal: Journal of neuro-oncology
Published: October 10, 2016
View All 3 Publications
Similar Doctors
Leonel Kahn
Advanced in Fibrosarcoma
Dr. Leonel Kahn
Radiation Oncology
Advanced in Fibrosarcoma
Dr. Leonel Kahn
Radiation Oncology

Piedmont Physicians Radiation Oncology Kennesaw

187 Chastain Rd Nw, Ste 120, 
Kennesaw, GA 
 (19.4 miles away)
770-218-6480
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Leonel Kahn, MD is a board-certified radiation oncologist with Peachtree Radiation Oncology Services. He joined the group in 2018 and practices at Piedmont Kennesaw, Piedmont Atlanta Hospital, and Piedmont West. He practices general radiation oncology and has extensive experience with modern radiation oncology techniques (intensity modulated radiation therapy, image guided radiation therapy, and stereotactic body radiotherapy). He has a special interest in gastrointestinal, breast, and central nervous system malignancies. He has additional training in stereotactic radiosurgery (Gamma Knife and linear accelerator-based radiosurgery) for malignant and benign conditions.Dr. Kahn is an enthusiastic and committed physician. His skill sets are particularly suited to bridge the gap between the systematic processes of treatment planning and delivery versus the warmhearted nature of caring for cancer patients. He is a critical thinker and enjoys the process of assimilating scientific evidence with patient-specific factors to determine the best treatment decision. His experience has refined his ability to make decisive choices in the face of complex cancer care. He also establishes deep bonds with his patients, grounded in compassion and empathy. He thrives on the demanding nature of the profession in terms of learning and updating his knowledge base as the field constantly evolves. Importantly, radiation oncology is a field in which he feels endlessly honored and humbled to work.In addition to his clinical responsibilities, he is a voting member of the Piedmont Healthcare Institutional Review Board. He also has comprehensive training in clinical trial enrollment to national cooperative group protocols. He enjoys discussing potential clinical trials with patients, if it is in line with their wishes.He attended Tulane University in New Orleans, Louisiana, where he received a Bachelor of Science in Neuroscience (Summa Cum Laude). He then earned his medical degree from Oregon Health and Science University in Portland, Oregon. For his graduate medical education, he performed an internship at Legacy Health System in Portland, Oregon and completed a radiation oncology residency at the University of California, Davis Comprehensive Cancer Center in Sacramento, California. He served as chief radiation oncology resident during his final year. Dr. Kahn was born in Louisiana, but raised in Eugene, Oregon. Walking his corgi dog and cooking are the two ways he spends most of his weekends. He is also very happily married. Dr. Kahn is rated as a Distinguished provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Anal Cancer, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Pleuropulmonary Blastoma.

Advanced in Fibrosarcoma
Dr. Shelley Machuta-Fernandes
Radiation Oncology
Advanced in Fibrosarcoma
Dr. Shelley Machuta-Fernandes
Radiation Oncology
1100 Northside Forsyth Dr, Ste 140, 
Cumming, GA 
 (29.5 miles away)
770-292-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shelley Machuta-Fernandes is a Radiation Oncologist in Cumming, Georgia. Dr. Machuta-Fernandes is rated as an Advanced provider by MediFind in the treatment of Fibrosarcoma. Her top areas of expertise are Breast Cancer, Pleuropulmonary Blastoma, Alveolar Soft Part Sarcoma, and Familial Prostate Cancer. Dr. Machuta-Fernandes is currently accepting new patients.

Advanced in Fibrosarcoma
Dr. Jonathan T. Whaley
Radiation Oncology
Advanced in Fibrosarcoma
Dr. Jonathan T. Whaley
Radiation Oncology

Memorial Health Partners Foundation, Inc

615 E Villanow St, 
La Fayette, GA 
 (79.6 miles away)
706-638-1606
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jonathan Whaley is a Radiation Oncologist in La Fayette, Georgia. Dr. Whaley is rated as a Distinguished provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Cervical Cancer, and Neuroendocrine Carcinoma of the Cervix. Dr. Whaley is currently accepting new patients.

VIEW MORE FIBROSARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nowlan's expertise for a condition
ConditionClose
    • Distinguished
    • Anal Cancer
      Dr. Nowlan is
      Distinguished
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Astrocytoma
      Dr. Nowlan is
      Distinguished
      . Learn about Astrocytoma.
      See more Astrocytoma experts
    • Brain Tumor
      Dr. Nowlan is
      Distinguished
      . Learn about Brain Tumor.
      See more Brain Tumor experts
    • Lung Cancer
      Dr. Nowlan is
      Distinguished
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    • Metastatic Brain Tumor
      Dr. Nowlan is
      Distinguished
      . Learn about Metastatic Brain Tumor.
      See more Metastatic Brain Tumor experts
    • Pleuropulmonary Blastoma
      Dr. Nowlan is
      Distinguished
      . Learn about Pleuropulmonary Blastoma.
      See more Pleuropulmonary Blastoma experts
    View All 7 Distinguished Conditions
    • Advanced
    • Angiosarcoma
      Dr. Nowlan is
      Advanced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Arteriovenous Malformation
      Dr. Nowlan is
      Advanced
      . Learn about Arteriovenous Malformation.
      See more Arteriovenous Malformation experts
    • Atypical Teratoid Rhabdoid Tumor (ATRT)
      Dr. Nowlan is
      Advanced
      . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
      See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
    • Breast Cancer
      Dr. Nowlan is
      Advanced
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Embryonal Tumor with Multilayered Rosettes
      Dr. Nowlan is
      Advanced
      . Learn about Embryonal Tumor with Multilayered Rosettes.
      See more Embryonal Tumor with Multilayered Rosettes experts
    • Ependymoma
      Dr. Nowlan is
      Advanced
      . Learn about Ependymoma.
      See more Ependymoma experts
    View All 19 Advanced Conditions
    • Experienced
    • Acoustic Neuroma
      Dr. Nowlan is
      Experienced
      . Learn about Acoustic Neuroma.
      See more Acoustic Neuroma experts
    • Adult Soft Tissue Sarcoma
      Dr. Nowlan is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Nowlan is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Alveolar Soft Part Sarcoma
      Dr. Nowlan is
      Experienced
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    • Awake Craniotomy
      Dr. Nowlan is
      Experienced
      . Learn about Awake Craniotomy.
      See more Awake Craniotomy experts
    • Bone Tumor
      Dr. Nowlan is
      Experienced
      . Learn about Bone Tumor.
      See more Bone Tumor experts
    View All 73 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

        Close
        0 / 1000

        Please provide us with the below insurance information:

                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.